Disease Modification in Myelofibrosis: An Elusive Goal?
Author:
Affiliation:
1. Department of Medicine, Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL
2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.21.02246
Reference85 articles.
1. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms
2. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
3. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
4. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
5. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Moving toward disease modification in polycythemia vera;Blood;2023-11-30
2. A Novel Subtype of Myeloproliferative Neoplasms Driven by a MYC-Alarmin Axis;2023-09-26
3. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments;Cancers;2023-06-24
4. Emerging Treatment Options for Myelofibrosis: Focus on Anemia;Therapeutics and Clinical Risk Management;2023-06
5. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy;Expert Opinion on Pharmacotherapy;2023-05-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3